Previous

Diabetes, Cardiovascular & Renal Complications

28 Nov 2012 - 29 Nov 2012

Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors Review clinical results from the DEMAND study Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments